Trius Therapeutics Inc (TSRX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access TSRX Annual Income Statement →
Quarterly income statement trends provide context on Trius Therapeutics Inc's margins, operating leverage, and earnings trajectory.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2013)
Q2 2013
(Mar 31 2013) (Dec 31 2012) (Sep 30 2012) (Jun 30 2012)
Revenues
Contracts Revenue0.26
Total Revenue1.29
Costs & Expenses
Gross Profit1.29
Selling, Administration, Marketing5.54
Research and Development Expense14.68
Other Operating Expense / -Income0.00
Total operating costs including COS20.23
Operating income / -loss-18.94
Net Interest Expense / -Income0.00
Other loss / -income-0.01
Total costs & expenses20.97
Income & Taxes
Income / -loss before income taxes-19.68
Income after income taxes-19.68
Income / -loss from continuing operations-19.68
Net income / -loss-19.68
Income / -loss to shareholder-19.68
EBIT-19.68
EBITD-19.50
EBITDA-19.50
Earnings Per Share
Basic EPS (excl. extra items)-0.41
Basic Net EPS-0.41
Basic shares outstanding (Mill. of Units)47.95
Diluted Net EPS-0.41
Diluted average shares (Mill. of Units)47.95
4 historic quarters locked

Sign in to unlock the full Trius Therapeutics Inc income statement history.

About TSRX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.